PL389364A1 - Nowe zastosowanie pochodnych 2-pirolidonu - Google Patents

Nowe zastosowanie pochodnych 2-pirolidonu

Info

Publication number
PL389364A1
PL389364A1 PL389364A PL38936409A PL389364A1 PL 389364 A1 PL389364 A1 PL 389364A1 PL 389364 A PL389364 A PL 389364A PL 38936409 A PL38936409 A PL 38936409A PL 389364 A1 PL389364 A1 PL 389364A1
Authority
PL
Poland
Prior art keywords
new applications
pyrrolidone derivatives
pyrrolidone
derivatives
applications
Prior art date
Application number
PL389364A
Other languages
English (en)
Inventor
Rafał Olszanecki
Beata Bujak-Giżycka
Ryszard Korbut
Mariusz Gajda
Original Assignee
Uniwersytet Jagielloński
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Jagielloński filed Critical Uniwersytet Jagielloński
Priority to PL389364A priority Critical patent/PL389364A1/pl
Priority to PCT/PL2010/050053 priority patent/WO2011049475A1/en
Priority to US13/503,556 priority patent/US8686037B2/en
Priority to JP2012535158A priority patent/JP5898084B2/ja
Priority to EP10787204A priority patent/EP2490686A1/en
Publication of PL389364A1 publication Critical patent/PL389364A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL389364A 2009-10-23 2009-10-23 Nowe zastosowanie pochodnych 2-pirolidonu PL389364A1 (pl)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PL389364A PL389364A1 (pl) 2009-10-23 2009-10-23 Nowe zastosowanie pochodnych 2-pirolidonu
PCT/PL2010/050053 WO2011049475A1 (en) 2009-10-23 2010-10-23 The new application of 2-pyrrolidone derivatives
US13/503,556 US8686037B2 (en) 2009-10-23 2010-10-23 Use of piracetam for treating diabetic nephropathy
JP2012535158A JP5898084B2 (ja) 2009-10-23 2010-10-23 ２−ピロリドン誘導体の新規な適用
EP10787204A EP2490686A1 (en) 2009-10-23 2010-10-23 The new application of 2-pyrrolidone derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL389364A PL389364A1 (pl) 2009-10-23 2009-10-23 Nowe zastosowanie pochodnych 2-pirolidonu

Publications (1)

Publication Number Publication Date
PL389364A1 true PL389364A1 (pl) 2011-04-26

Family

ID=43709004

Family Applications (1)

Application Number Title Priority Date Filing Date
PL389364A PL389364A1 (pl) 2009-10-23 2009-10-23 Nowe zastosowanie pochodnych 2-pirolidonu

Country Status (5)

Country Link
US (1) US8686037B2 (pl)
EP (1) EP2490686A1 (pl)
JP (1) JP5898084B2 (pl)
PL (1) PL389364A1 (pl)
WO (1) WO2011049475A1 (pl)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1039113A (en) 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
FI51098C (fi) 1975-03-27 1976-10-11 Medipolar Oy Menetelmä terapeuttisesti arvokkaan 2-okso-1-pyrrolidinyyliasetamidin valmistamiseksi.
BE864269A (fr) 1977-03-03 1978-06-16 Parke Davis & Co Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire
JPH0987178A (ja) 1995-09-22 1997-03-31 Toyama Chem Co Ltd 神経成長因子の作用増強剤
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
RO121085B1 (ro) * 1999-12-01 2006-12-29 Ucb, S.A., Utilizarea levetiracetamului, în tratamentul bolilor sistemului nervos central
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
CN1484527A (zh) 2000-12-28 2004-03-24 ��һ��������ҩ��ʽ���� 神经性疼痛治疗和预防药
AU2002307327A1 (en) * 2001-05-04 2002-11-18 Eli Lilly And Company Use of an ampa receptor potentiator for the manufacture of a medicament for the treatment of type 2 diabetes
JP2003226642A (ja) * 2002-02-01 2003-08-12 Dai Ichi Seiyaku Co Ltd 眼疾患予防及び／又は治療薬

Also Published As

Publication number Publication date
EP2490686A1 (en) 2012-08-29
US8686037B2 (en) 2014-04-01
US20120258997A1 (en) 2012-10-11
JP5898084B2 (ja) 2016-04-06
WO2011049475A1 (en) 2011-04-28
JP2013508357A (ja) 2013-03-07

Similar Documents

Publication Publication Date Title
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
ZA201203615B (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
EP2438246A4 (en) CONSTRUCTION ASPECTS
IL221170A0 (en) Processes of synthesizing dihydropyridophthalazinone derivatives
GB0920382D0 (en) Design of molecules
ZA201006719B (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
ZA201102604B (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
PL2133419T3 (pl) Zastosowania beta-dipeptydów cyjanoficyny
EP2231687A4 (en) NEW DERIVATIVES OF ACYL-CYANPYRROLIDINES
GB0820698D0 (en) Uses of immunomodulators
PL2440558T3 (pl) Związki dihydropirolonaftyrydynony jako inhibitory JAK
GB0817926D0 (en) Articles of clothiing
PL2329054T3 (pl) Wytwarzanie stopów żelaza
ZA201200751B (en) Fluorinated derivatives of 3-hydroxypyridin-4-ones
GB0910078D0 (en) Uses of mannose-6-phosphate
GB0922023D0 (en) Preparation of n-monofluoroalkyl compounds
GB0903740D0 (en) Mrthod for reducing the viscosity of biosolids
IL214958A0 (en) Novel uses of fibrinogen
EP2459540A4 (en) PREPARATION OF FIPAMEZOLE
SI2504309T1 (sl) Sinteza acetokslacetaldehida
EP2331490A4 (en) PREPARATION OF DIBUTOXYMETHANE
GB0816419D0 (en) Production of hydroelecticity
ZA201200531B (en) Pharmaceutical composition of rifampicin
GB0821710D0 (en) Derivatives of dihydroindolone
GB0905280D0 (en) Novel uses of VEGFxxxb